LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Ligand Pharmaceuticals Inc

Cerrado

SectorSanidad

184.08 -1.31

Resumen

Variación precio

24h

Actual

Mínimo

178.73

Máximo

187.57

Métricas clave

By Trading Economics

Ingresos

112M

117M

Ventas

115M

P/B

Media del Sector

81.987

121.746

Margen de beneficios

101.569

Empleados

68

EBITDA

87M

149M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+26.89% upside

Dividendos

By Dow Jones

Próximas Ganancias

26 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-440M

3.7B

Apertura anterior

185.39

Cierre anterior

184.08

Noticias sobre sentimiento de mercado

By Acuity

20%

80%

29 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 feb 2026, 23:47 UTC

Acciones populares

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 feb 2026, 22:59 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Grab Holdings to Buy U.S.-Based Stash Financial

11 feb 2026, 23:54 UTC

Ganancias

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 feb 2026, 23:50 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

11 feb 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 feb 2026, 23:49 UTC

Ganancias

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 feb 2026, 23:45 UTC

Ganancias

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 feb 2026, 23:42 UTC

Ganancias

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 feb 2026, 23:41 UTC

Ganancias

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 feb 2026, 23:40 UTC

Ganancias

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 feb 2026, 23:35 UTC

Charlas de Mercado

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 feb 2026, 23:18 UTC

Charlas de Mercado

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 feb 2026, 23:14 UTC

Charlas de Mercado

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 feb 2026, 22:59 UTC

Ganancias

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 feb 2026, 22:59 UTC

Ganancias

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 feb 2026, 22:59 UTC

Ganancias

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 feb 2026, 22:58 UTC

Ganancias

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 feb 2026, 22:57 UTC

Ganancias

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 feb 2026, 22:54 UTC

Ganancias

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 feb 2026, 22:53 UTC

Ganancias

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 feb 2026, 22:47 UTC

Ganancias

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 feb 2026, 22:47 UTC

Ganancias

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 feb 2026, 22:23 UTC

Ganancias

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 feb 2026, 22:22 UTC

Ganancias

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 feb 2026, 22:22 UTC

Ganancias

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 feb 2026, 22:19 UTC

Ganancias

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 feb 2026, 22:18 UTC

Ganancias

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 feb 2026, 22:18 UTC

Ganancias

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 feb 2026, 22:18 UTC

Ganancias

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 feb 2026, 22:16 UTC

Ganancias

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Comparación entre iguales

Cambio de precio

Ligand Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

26.89% repunte

Estimación a 12 Meses

Media 237.2 USD  26.89%

Máximo 270 USD

Mínimo 220 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ligand Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

6

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

102.5 / 109.24Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

29 / 352 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat